TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15567936
Drug: Single-agent docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-agent docetaxel (T)
Study: 15567936
Drug: Single-agent doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-agent doxorubicin (A)
Study: 6788275
Drug: Naftidrofuryl infusion
Normalized name: naftidrofuryl
DrugBank: Naftidrofuryl (DB13588)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naftidrofuryl infusion
Study: 24412801
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg DKP
Study: 24412801
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg DKP
Study: 22333955
Drug: Classification-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Classification-based treatment approach
Study: 22258622
Drug: Usual physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual physical therapy care
Study: 17071953
Drug: Branded drugs
Normalized name: Eagle Brand Medicated Oil
DrugBank: Eucalyptus oil (DB11114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Branded drugs
Study: 14687051
Drug: Misoprostol (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol (25 mcg, hospital-prepared capsule)
Study: 14687051
Drug: Dinoprostone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dinoprostone (1 mg gel)
Study: 10723516
Drug: Stavudine-based multiple
Normalized name: Stavudine
DrugBank: Stavudine (DB00649)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stavudine-based multiple agent combinations (including protease inhibitor-containing and -sparing regimens, triple nucleoside RTI regimens, and regimens including non-nucleoside RTIs and/or hydroxyurea)
Study: 10723516
Drug: Stavudine-based multiple
Normalized name: Stavudine
DrugBank: Stavudine (DB00649)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stavudine-based multiple agent combinations
Study: 7712309
Drug: Interferon-alpha (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon-alpha (5 MU daily for 6 months)
Study: 7712309
Drug: Interferon-alpha (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon-alpha (5 MU three times per week or daily for 6 months)
Study: 31178940
Drug: High medication
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High medication necessity belief
Study: 31178940
Drug: Negative belief
Normalized name: Ora Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative belief toward medications
Study: 31178940
Drug: Low medication
Normalized name: Dianeal Low Calcium 1.5 Intraperitoneal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low medication necessity belief
Study: 31178940
Drug: High medication
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High medication concern belief
Study: 30478263
Drug: Negative medication
Normalized name: GLYCERIN NEGATIVE CONTROL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative medication belief
Study: 31178940
Drug: Nonadherence to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonadherence to medications
Study: 26565077
Drug: Dalfampridine ER
Normalized name: Dalfampridine ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalfampridine ER 10 mg BID
Study: 26565077
Drug: Dalfampridine ER
Normalized name: Dalfampridine ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalfampridine ER 5 mg BID
Study: 23563245
Drug: n-3 fatty
Normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 fatty acids (1.7 g DHA and 0.6 g EPA)
Study: 17078155
Drug: Losartan-based antihypertensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan-based antihypertensive treatment
Study: 19407804
Drug: Atenolol-based antihypertensive
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atenolol-based antihypertensive treatment
Study: 17956497
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg sulphadoxine/2.5 mg pyrimethamine
Study: 7754939
Drug: Enalapril treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril treatment initiated < 24 hours after AMI
Study: 2279540
Drug: no further
Approvals — FDA: no, EMA: no, PMDA: no
Description: no further treatment (control group)
Study: 6793924
Drug: Acetylsalicylate of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetylsalicylate of lysine (1.8 g)
Study: 6793924
Drug: Acetylsalicylate of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetylsalicylate of lysine (3.6 g)
Study: 375401
Drug: Pentazocine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentazocine (60 mg)
Study: 26303134
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate 500 μg BID for 8 weeks
Study: 23525738
Drug: High-dose sevoflurane
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose sevoflurane (1.5 MAC)
Study: 23525738
Drug: Moderate-dose sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moderate-dose sevoflurane (1.0 MAC)
Study: 23525738
Drug: Low-dose sevoflurane
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose sevoflurane (0.5 MAC)
Study: 21488754
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g of English walnuts per day for 30 days
Study: 21488754
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g of black walnuts per day for 30 days
Study: 15923688
Drug: Nutrition education
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutrition education intervention delivered monthly by trained counsellors
Study: 11973440
Drug: Oral 17beta-estradiol
Normalized name: Estradiol-17beta
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral 17beta-estradiol 1 mg daily continuously combined with dydrogesterone 2.5 mg daily
Study: 11973440
Drug: Oral 17beta-estradiol
Normalized name: Estradiol-17beta
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral 17beta-estradiol 1 mg daily continuously combined with dydrogesterone 5 mg daily
Study: 11973440
Drug: Oral 17beta-estradiol
Normalized name: Estradiol-17beta
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral 17beta-estradiol 1 mg daily continuously combined with dydrogesterone 10 mg daily
Study: 11973440
Drug: Oral 17beta-estradiol
Normalized name: Estradiol-17beta
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral 17beta-estradiol 1 mg daily continuously combined with dydrogesterone 20 mg daily
Study: 11973440
Drug: Oral 17beta-estradiol
Normalized name: Estradiol-17beta
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral 17beta-estradiol 1 mg daily continuously combined with dydrogesterone 2.5 to 20 mg daily
Study: 9819446
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with interferon alfa-2b and ribavirin (1000 or 1200 mg orally per day) for 24 weeks
Study: 9819446
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with interferon alfa-2b and ribavirin (1000 or 1200 mg orally per day) for 48 weeks
Study: 9819446
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy for 24 weeks
Study: 9819446
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy for 48 weeks
Study: 8961
Drug: Single intracarotid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intracarotid injection of phenoxybenzamine
Study: 8961
Drug: Prolonged treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged treatment with propranolol
Study: 28545564
Drug: Sufentanil 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil 1.0 μg ml‐1 plus dexmedetomidine 4 μg ml‐1 (Group SD)
Study: 28545564
Drug: Sufentanil 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil 1.0 μg ml‐1 (Group S)
Study: 25213114
Drug: Cognitive behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behaviour therapy-based programme
Study: 24376277
Drug: Behavioral support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral support sessions plus 7 weeks of bupropion therapy (BSS+)
Study: 21566568
Drug: Erythromycin (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (12.5 mg kg(‐1) per day)
Study: 21566568
Drug: UDCA (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: UDCA (5 mg kg(‐1) every 6 h)
Study: 17449575
Drug: Sodium hyaluronate
Normalized name: sodium hyaluronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium hyaluronate (NaH, 300 mg)
Study: 17449575
Drug: Chondroitin sulfate
Normalized name: Chondroitin Sulfate
DrugBank: Chondroitin sulfate (DB09301)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chondroitin sulfate (CS, 360 mg)
Study: 24938324
Drug: Propranolol at
Normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol at 80 mg/day plus HFA-BDP at 100 μg/day
Study: 24938324
Drug: HFA-BDP at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFA-BDP at 400 μg/day
Study: 22874535
Drug: Potassium nitrate
Normalized name: Potassium Nitrate
DrugBank: Potassium (DB14500)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Potassium nitrate (614-mg nitrate)
Study: 19337557
Drug: Omega-3 PUFAs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 PUFAs plus rosuvastatin 10 mg
Study: 19337557
Drug: Rosuvastatin 10
Normalized name: rosuvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 10 mg alone
Study: 19337557
Drug: Omega-3 PUFAs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 PUFAs added to rosuvastatin 10 mg
Study: 16250069
Drug: Olanzapine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (2.5 to 7.5 mg/d)
Study: 16250069
Drug: Olanzapine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (2.5 to 7.5 mg/d) in patients with MMSE scores of 14-18 (n = 35)
Study: 16250069
Drug: Olanzapine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (2.5 to 7.5 mg/d) in patients with MMSE scores of 23-26 (n = 78)
Study: 10229732
Drug: GV150526 (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: GV150526 (800 mg loading dose followed by 400 mg BID maintenance)
Study: 10229732
Drug: GV150526 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: GV150526 (200 mg BID maintenance)
Study: 8916624
Drug: Cognitive Therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Therapy (CT) and Interpersonal Therapy (IPT)
Study: 6871083
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg almitrine
Study: 6871083
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg almitrine
Study: 24957863
Drug: Mosapride 5
Normalized name: mosapride 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mosapride 5 mg thrice daily plus Omeprazole 10 mg once daily (GO group)
Study: 19174703
Drug: Gemfibrozil (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemfibrozil (600 mg twice a day) plus American phase 3 diet for 2 months
Study: 17438705
Drug: Experimental treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental treatment (chemotherapy)
Study: 15975358
Drug: Aspirin and
Normalized name: Aspirin and Caffeine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin and clopidogrel therapy with intraoperative aprotinin
Study: 15975358
Drug: Placebo for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for 5 days before surgery and placebo infusions intraoperatively
Study: 10357038
Drug: Once weekly
Normalized name: Actonel 35 4-Week Once Weekly Dosepack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once weekly ECT
Study: 9821454
Drug: High stimulus
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High stimulus dose with once weekly ECT
Study: 7714075
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg melatonin (1 mg at 0800, 1000, and 1200 h)
Study: 2845199
Drug: Deferoxamine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferoxamine (30 mg/kg IV before and after bypass, 250 mg/L in cardioplegic solution)
Study: 31621901
Drug: Intervention (INT)
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intervention (INT) - Geriatric Acute and Post-Acute Fall Prevention Intervention (GAPcare) including medication therapy management by a pharmacist and fall risk assessment by a physical therapist.
Study: 31337525
Drug: Catheter ablation
Normalized name: CATHETER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Catheter ablation (CA) with anticoagulant therapy using edoxaban
Study: 14518608
Drug: L-arginine (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (8 g p.o. two times daily) for 14 days
Study: 14518608
Drug: L-arginine (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (8 g p.o. two times daily)
Study: 14518608
Drug: L-arginine and
Normalized name: Amino Acid, Amino Acids 5% (L-Arginine and L-Lysine) intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine and placebo
Study: 10830415
Drug: tolcapone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: tolcapone (50 mg, 200 mg, or 400 mg three times a day)
Study: 9014744
Drug: Intravenous clodronate
Normalized name: Clodronic acid
DrugBank: Clodronic acid (DB00720)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous clodronate (1800 mg) combined with MivP chemotherapy
Study: 9014744
Drug: MivP chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MivP chemotherapy alone
Study: 9014744
Drug: Lower doses
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower doses of intravenous clodronate combined with MivP
Study: 3944815
Drug: Atropine 1.2
Normalized name: ATROPINE 1.2/NEOSTIGMINE 2.5MG/VIL INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine 1.2 mg
Study: 6507825
Drug: Glycopyrronium 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrronium 0.6 mg
Study: 30342697
Drug: Once weekly
Normalized name: Actonel 35 4-Week Once Weekly Dosepack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once weekly dressing changes with negative pressure wound therapy (NPWT)
Study: 30342697
Drug: Thrice weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrice weekly dressing changes with negative pressure wound therapy (NPWT)
Study: 28007665
Drug: Daclizumab 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daclizumab 0.3 mg/kg
Study: 28007665
Drug: Daclizumab 1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daclizumab 1.2 mg/kg
Study: 26139733
Drug: Propofol 1
Normalized name: propofol 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 1 mg/kg IV bolus followed by 0.5 mg/kg (Group P)
Study: 26139733
Drug: Etomidate 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etomidate 0.1 mg/kg followed by 0.05 mg/kg (Group E)
Study: 15203886
Drug: Nicotinamide 50
Normalized name: Nicotinamide 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotinamide 50 mg/kg
Study: 11466137
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of rt-PA
Study: 9479357
Drug: TOR 60
Normalized name: ivacaftor 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: TOR 60 mg daily
Study: 9479357
Drug: TOR 240
Normalized name: intrinsic factor 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: TOR 240 mg daily
Study: 9479357
Drug: TAM 40
Normalized name: piracetam 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAM 40 mg daily
Study: 7931484
Drug: VCR, AMD,
Approvals — FDA: no, EMA: no, PMDA: no
Description: VCR, AMD, and radiation therapy
Study: 7931484
Drug: VCR, AMD,
Approvals — FDA: no, EMA: no, PMDA: no
Description: VCR, AMD, DOX, and radiation therapy
Study: 2979259
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg cimetidine b.d. for up to 6 weeks
Study: 29500310
Drug: Once-daily Norditropin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily Norditropin
Study: 28211028
Drug: rhGH administration
Normalized name: rhGH
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhGH administration (0.029 mg kg-1 BW; 6 days/week for 3 weeks)
Study: 9085026
Drug: 0.2% chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% chlorhexidine treatment
Study: 9085026
Drug: Control (water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (water treatment)
Study: 3996841
Drug: Cimetidine, two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine, two doses of 400 mg
Study: 3996841
Drug: Cimetidine, four
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine, four doses of 400 mg
Study: 3996841
Drug: Ranitidine, two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine, two doses of 150 mg
Study: 3996841
Drug: Ranitidine, two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine, two doses of 300 mg
Study: 30878897
Drug: Intravenous labetalol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous labetalol (20 mg initially, escalating doses up to 300 mg)
Study: 30878897
Drug: Oral nifedipine
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral nifedipine (10 mg initially, escalating doses up to 90 mg)
Study: 24168291
Drug: 1-ml injection
Normalized name: ethyl chloride 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-ml injection of platelet-rich plasma (PRP)
Study: 24168291
Drug: 1-ml injection
Normalized name: ethyl chloride 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-ml injection of platelet-poor plasma (PPP)
Study: 20189753
Drug: IV paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV paracetamol 1 g every 6 hours and IV meperidine
Study: 18050629
Drug: Medication group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication group (Brufen sustained-release capsules, 0.3 mg, b.i.d. for 3 days)
Study: 15591725
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (AC) following the guidelines of the German Cancer Society (GCS)
Study: 6171099
Drug: Intranasal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal administration of 5 mg polyguacyl
Study: 6171099
Drug: Aerosol administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerosol administration of polyguacyl
Study: 6171099
Drug: Intranasal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal administration of live influenza A (H1N1) vaccine
Study: 23466353
Drug: 6% coriander
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% coriander oil in unguentum leniens applied twice daily
Study: 16584436
Drug: Aprotinin (AP)
Normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aprotinin (AP) 280 mg followed by 70 mg per hour
Study: 16584436
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TA) 40 mg per kg followed by 40 mg per kg per hour
Study: 53548
Drug: Prophylactic oral
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic oral metronidazole and kanamycin
Study: 53548
Drug: Dietary and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary and mechanical preparation alone
Study: 7386225
Drug: Ampicillin in
Normalized name: ampicillin Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin in a daily dose of 30 g for three days and 20 g for four days (excessive doses)
Study: 7386225
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (moderate doses of ampicillin for one month)
Study: 29617814
Drug: DPX-RSV(A) 10-μg
Normalized name: immunoglobulin G, human 10 % Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: DPX-RSV(A) 10-μg
Study: 29617814
Drug: DPX-RSV(A) 25-μg
Normalized name: tretinoin
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DPX-RSV(A) 25-μg
Study: 23249758
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate 150 mg/day from day 3 to day 7 of the cycle (n=145)
Study: 23249758
Drug: High doses
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High doses of gonadotropins (GnRH agonist 0.1 mg and recombinant FSH 450 IU daily) (n=146)
Study: 19169912
Drug: Triamcinolone cream
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone cream
Study: 12139205
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg once daily (OD) alfuzosin
Study: 12139205
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg three times daily (TID) alfuzosin
Study: 7840365
Drug: Cognitive Behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavior Therapy
Study: 1697914
Drug: YM617 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: YM617 0.4 mg
Study: 1697914
Drug: YM617 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: YM617 0.2 mg
Study: 1697914
Drug: YM617 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: YM617 0.1 mg
Study: 17536871
Drug: Tobramycin (300mg/4mL)
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tobramycin (300mg/4mL) administered twice daily via nebulizer for 4 weeks
Study: 17536871
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered twice daily via nebulizer for 4 weeks
Study: 14973517
Drug: Losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 50 mg/hydrochlorothiazide 12.5 mg (L/H)